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OPIOID-NORNICOTINE CODRUGS 
COMBINATIONS FOR PAIN MANAGEMENT 
This application claims priority from U.S. Provisional 
Patent Application No. 61/072,091, filed Mar. 27, 2008, the 
disclosure of which is hereby incorporated by reference in its 
entirety. 
FIELD OF THE INVENTION 
The present invention relates to the field of pain manage 
ment, and more particularly to synergistic codrugs compris 
ing an opioid and nomicotine which have been combined to 
form a single chemical codrug entity. When the codrug is 
administered it produces a synergistic analgesic response to 
pain. 
BACKGROUND OF INVENTION 
Opioids are any endogenous or exogenous compounds that 
bind to an opioid receptor. Opioid receptors are localiZed 
primarily in the brain, spinal cord, and gastrointestinal tract. 
When opioids bind to their receptors in the brain and spinal 
cord they block pain transmission signals from the periphery 
of the body. Although opioids are very effective for moderate 
to severe pain, there are many well known problems associ 
ated with opioid therapy. Those problems include serious side 
effects such as cognitive dysfunction, respiratory depression, 
nausea/vomiting, urinary retention, and constipation. Fur 
ther, chronic opioid therapy often results in the development 
of tolerance to the analgesic effect, resulting in dose escala 
tion, as well as physical and psychological dependence. 
Nornicotine, the primary metabolite of nicotine, binds to 
nicotinic receptors which are located in the brain, spinal cord 
and periphery (autonomic ganglia and smooth muscle). It has 
recently been appreciated that nicotinic receptor binding can 
also modulate pain signals to the brain suggesting their poten 
tial use in the treatment of pain (acute, chronic, cancer-re 
lated). 
There is a great need for analgesic medications able to 
provide high eñicacy pain relief while providing more favor 
able pharmacokinetics and reducing the possibility of unde 
sirable effects. Enhancement of the analgesic effect of opio 
ids as well as nornicotine has been described in the art 
Therefore, there is a need for a way to administer opioids and 
nornicotine to provide a more favorable pharmacokinetic pro 
file. 
SUMMARY OF THE INVENTION 
The present invention provides a codrug of the following 
formula: 
Opioid Nomicotine 
as well as pharmaceutical compositions thereof. The linker 
may be 
m 
20 
25 
40 
50 
60 
65 
whereinY is O or S; R1 is an opioid moiety; and R2-N?R3 
is a nornicotine moiety; or 
H 
O X N 
Rl/ T T \R2 
O O 
wherein X is nothing, O, S, NH, NR4 (where R4:alkyl), 
(CH2),C (where X11-20, and alkyl is linear or branched), and 
wherein Rl-O is an opioid moiety and R2-N?R3 is a 
nornicotine moiety. 
In another embodiment, the present invention provides a 
method of of synthesis of a codrug comprising a linker, an 
opioid and a nornicotine, said method comprising: a) 
covalently bonding a first attachment point ofthe linker to the 
opioid; b) covalently bonding a second attachment point of 
the linker to the nornicotine; and c) recovering the codrug, 
wherein the nornicotine is selected from the group consisting 
of S-nornicotine, R-nomicotine, and racemic nornicotine. 
In another embodiment, the present invention provides a 
method of treatment comprising: joining an opioid together 
with a nornicotine using a linker to form a cleavable codrug; 
and administering an analgesically effective amount of the 
codrug to a humanpatient, wherein the nornicotine is selected 
from the group consisting of S-nornicotine, R-nomicotine, 
and racemic nornicotine. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a graph illustrating the effect of S-normcotine 
(S-NNIC) and morphine (MOR) combinations thermal anti 
nociception, using the tail flick test. 
FIG. 2 is a graph illustrating the effect of S-normcotine 
(S-NNIC) and morphine (MOR) combinations mechanical 
hyperalgesia. 
FIG. 3 shows codrug of 3-acetylmorphine and S-nomico 
tine of GC-MS of acetyl morphine. 
FIG. 4 shows H-NMR analysis of acetyl morphine. 
FIG. 5 shows C-NMR of acetyl morphine. 
FIG. 6 shows ESI-MS of the para-nitrophenoxycarbamate 
ester of codeine. 
FIG. 7 shows H-NMR analysis of the para-nitrophenoXy 
carbamate ester of codeine. 
FIG. 8 shows C-NMR of the para-nitrophenoxycarbamate 
ester of codeine. 
FIG. 9 shows H-NMR of an acetyl morphine and S-norm 
cotine codrug. 
FIG. 10 shows C-NMR of an acetyl morphine and S-nor 
nicotine codrug. 
FIG. 11 shows H-NMR analysis of an intermediate in the 
preparation of a codrug of codeine and S-nomicotine. 
FIG. 12 shows C-NMR analysis of an intermediate in the 
preparation of a codrug of codeine and S-nomicotine. 
FIG. 13 shows MALDI analysis of an intermediate in the 
preparation of a codrug of codeine and S-nomicotine. 
FIG. 14 shows H-NMR analysis of a codrug of codeine and 
S-nomicotine. 
















